Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07736586) titled 'A Study of HL40626S Tablets in Healthy Adults' on July 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Highslab Therapeutics, Inc.
Condition:
Psoriasis (PsO)
Skin Disease
Immune System Disease
Skin Diseases, Papulosquamous
Intervention:
Drug: HL40626S tablets
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 16, 2026
Target Sample Size: 64
Countries of Recruitment:
Australia
To know...